Report
Hyloris Pharma - Progressing on all fronts since the start of the year
*Last night, HYL announced the start of the Ph3 study with its asset ‘Tranexamic Acid Oral rinse', meant to control incidences of bleeding related to dental procedures.*Small positive news item indicating that the company is progressing on all fronts since the start of this year having announced as well new product additions and successful clinical readouts.*No impact on valuation and investment case. BUY reiterated in light of the TP upside and 2024 news flow.
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.